Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gansan Decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Hospital of Chengdu University of Traditional Chinese Medicine for the treatment of chronic hepatitis B (CHB). It is typically administered as an oral decoction and is being investigated as an adjunctive therapy to standard-of-care treatments, including peginterferon alpha-2b and nucleos(t)ide analogues (NAs). The formulation is designed to modulate the host immune system, aiming to enhance the clearance of hepatitis B surface antigen (HBsAg) and improve immune function in patients who have not achieved HBsAg loss through nucleos(t)ide analogue therapy alone. As a multi-herb decoction, it likely contains a variety of bioactive compounds that work synergistically to exert antiviral and immunomodulatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gansan Decoction.